The Top Line

Clinical trials reach a new automation inflection point (Sponsored)

Clinical development organizations are facing mounting pressure to do more with increasingly complex protocols, larger data sets and tighter timelines. While automation h

The future of RAS inhibitors

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotech

The people who stayed with the problem

The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from designing new proteins and developing cancer

Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)

The promise of precision medicine depends on more than scientific innovation. It also depends on whether eligible patients can be identified, tested and connected to the

MrBeast, Snapchat, AI and more: Pharma marketing’s pulse check

As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping how drugmakers and healthcare agencies reach au

 What did we learn from Big Pharma’s Q2 results?

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different. From the rollout of AI to the oral G

How consumerization is reshaping pharma marketing (Sponsored)

Consumerization is changing how patients engage with healthcare, and pharma companies may need to rethink how they approach awareness, diagnosis and commercialization.

A genomics library for the AI era

Having spent 14 years building out its capacity, Regeneron Genetics Center—the genomic research branch of the Tarrytown, New York-based pharma—is a pro when it comes to t

The next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)

The future of patient support may depend less on how much data organizations collect and more on how effectively they connect, govern and activate it. In this sponsored e

Novo Nordisk’s CFO on the oral Wegovy rollout and beyond

Novo Nordisk’s second-quarter earnings results this week were closely watched by analysts and investors eager to see whether the rollout of oral Wegovy could neutralize c

Inside Noble’s connected approach to patient support (Sponsored)

The continued shift toward self-administered therapies is changing how pharmaceutical companies think about patient support. While access and affordability remain priorit

Psychedelics, peptides and GLP-1s 

Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly’s Zepbound ads? And what are peptides?  This week on "The Top Line

GSK’s first lung cancer approval, a new IPO path and more

This week on "The Top Line," Fierce Healthcare and Life Sciences' editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stori

Why modern clinical trials need a finance-first strategy (Sponsored)

Clinical trial success depends on more than scientific rigor and operational execution. It also depends on the financial systems that support every stage of a study. In t

5 emerging biotech hubs

Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in bio

Operating at the speed of science: The new medical affairs playbook (Sponsored)

Medical affairs is at an inflection point. As science advances and healthcare professionals gain access to information in real time, medical teams face a mandate to deliv

Decision readiness is the next AI advantage (Sponsored)

AI is reshaping how organizations compete, but more data and more tools do not automatically lead to better decisions. In this episode of The Top Line, Justin Masterson,

A $10B deal, China trial scrutiny and highlights from ADA 2026

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer.

The deal before the deal

Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple. In this episode, recorded at Fierce Biotech Week, Senior E

FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)

In this sponsored episode of The Top Line, host Stephanie Butler is joined by Sheila Plant, vice president of regulatory affairs at Allucent, to examine how FDA Breakthro